Gene therapy for RPGR-related retinitis pigmentosa
Part of Eyes & vision clinical trials.
This trial tests a gene therapy for people with a specific genetic form of retinitis pigmentosa (caused by changes in the RPGR gene). It aims to improve vision and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to follow the study schedule, attend all visits, and sign a consent form.
- For the first part of the study, you need to be a male between 18 and 45 years old. For the second part, males aged 8 to 45 can join.
- You must have a clinical diagnosis of X-linked retinitis pigmentosa with symptoms like night blindness, tunnel vision, or vision loss.
- You cannot have other retinal degenerative diseases, such as those caused by different gene mutations, or have received gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study collects information from people who have a genetic change in the RP2 gene (a cause of inherited eye disease) and their families. It helps researchers learn more about the condition and how it affects daily life.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
Hear when a new X-Linked Retinitis Pigmentosa (XLRP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.